Catalyst Pharmaceuticals Inc CPRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CPRX is a good fit for your portfolio.
News
-
20 companies screened for quality in a cheap part of the stock market
-
20 companies screened for quality in a cheap -2-
-
20 companies screened for quality in a cheap part of the stock market
-
20 companies screened for quality in a cheap -2-
-
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
-
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day
-
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
-
Thinking about buying stock in Praxis Precision Medicines, Safety Shot, Catalyst Pharmaceuticals, Adicet Bio, or Exscientia?
Trading Information
- Previous Close Price
- $14.68
- Day Range
- $14.71–15.06
- 52-Week Range
- $11.09–17.77
- Bid/Ask
- $14.81 / $14.88
- Market Cap
- $1.76 Bil
- Volume/Avg
- 772,457 / 1.3 Mil
Key Statistics
- Price/Earnings (Normalized)
- 24.79
- Price/Sales
- 4.25
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 167
- Website
- https://www.catalystpharma.com
Comparables
Valuation
|
Metric
|
CPRX
|
VNDA
|
ITCI
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.79 | 62.87 | — |
Price/Book Value | 4.11 | 0.49 | 11.92 |
Price/Sales | 4.25 | 1.38 | 15.17 |
Price/Cash Flow | 9.36 | 19.63 | — |
Price/Earnings
CPRX
VNDA
ITCI
Financial Strength
|
Metric
|
CPRX
|
VNDA
|
ITCI
|
|---|---|---|---|
Quick Ratio | 2.51 | 4.82 | 4.95 |
Current Ratio | 2.88 | 4.94 | 5.41 |
Interest Coverage | — | — | — |
Quick Ratio
CPRX
VNDA
ITCI
Profitability
|
Metric
|
CPRX
|
VNDA
|
ITCI
|
|---|---|---|---|
Return on Assets (Normalized) | 52.88% | 2.20% | −13.47% |
Return on Equity (Normalized) | 63.91% | 2.62% | −15.88% |
Return on Invested Capital (Normalized) | 63.24% | 2.57% | −17.96% |
Return on Assets
CPRX
VNDA
ITCI
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Dvhpctply | Hkp | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Qkrxrtnn | Sjmqfw | $102.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Ktzzrfgw | Sdpwhj | $97.8 Bil | |
MRNA
| Moderna Inc | Ygjrmqgn | Plpkm | $41.3 Bil | |
ARGX
| argenx SE ADR | Wphkgzmmf | Jksj | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Rwbjnzzj | Gsxj | $21.0 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Xmlzspxkx | Kqvvyw | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Xwzrnxfvw | Pmynt | $15.4 Bil | |
RPRX
| Royalty Pharma PLC Class A | Xkmhtnyyt | Plpdg | $12.5 Bil | |
INCY
| Incyte Corp | Nnzqdybq | Bpkkw | $11.6 Bil |